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Purpose: Subacute combined degeneration (SCD) involves progressive degenera-
tion of the spinal cord, optic nerve, and peripheral nerves. Vitamin B12 (VB12) is a 
co-factor in myelin synthesis. Because each cell that constitutes the myelin compo-
nent in the central nervous system and peripheral nervous system is different, it is 
improbable that these cells undergo simultaneous degeneration. However, the se-
quence of degeneration in SCD has not been established. Materials and Methods: 
In this study, we analysed medical records and electrophysiological data of patients 
who showed neurological symptoms and whose serum VB12 levels were lower than 
200 pg/mL. Results: We enrolled 49 patients in this study. Their mean VB12 level 
was 68.3 pg/mL. Somatosensory evoked potential (SEP) study showed abnormal 
findings in 38 patients. Of the 40 patients who underwent visual evoked potential 
(VEP) study, 14 showed abnormal responses. Eighteen patients showed abnormal 
findings on a nerve conduction study (NCS). In this study, abnormal posterior tibial 
nerve SEPs only were seen in 16 patients, median nerve SEPs only were seen in 3 
patients, abnormal VEPs only in two, and abnormal NCS responses in one patient. 
No patient complained of cognitive symptoms. Conclusion: In SCD, degeneration 
appears to progress in the following order: lower spinal cord, cervical spinal cord, 
peripheral nerve/optic nerve, and finally, the brain.
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INTRODUCTION
Vitamin B12 (VB12) deficiency is thought to be an important cause of treatable neu-
rological diseases. Clinically, it affects the spinal cord, peripheral nerves, optic nerve, 
and brain.1,2 VB12 is a co-factor in myelin synthesis.3,4 Because of the heterogeneity 
of myelinating cells in the central nervous system (astrocyte and oligodendrocyte) 
and peripheral nervous system (Schwann cell), it is improbable that myelinating cells 
in the above tracts degenerate simultaneously. However, the sequence of degenera-
tion in subacute combined degeneration (SCD) has not been established.
Nutritional neuropathies, including those due to VB12 deficiency, are uncom-
mon in developed countries. However, in this era of intensive diabetes management, Sequential Involvement of the Nerve System in SCD
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DISCUSSION
Most of the patients (38/49, 78%) showed abnormal find-
ings on SEPs; among them, 16 showed only abnormal PT-
SEPs. A large number of patients who showed abnormal 
VEPs or NCS responses also showed abnormal SEPs. On 
the basis of these electrophysiological findings, we believe 
that abnormal PT-SEP is the first electrophysiological sign 
of SCD, followed by abnormal MN-SEP. Abnormal VEPs 
or NCS responses were observed after abnormal SEPs, but 
the order of generation of abnormal VEPs and NCS responses 
is unknown. Based on these electrophysiological findings, 
it may be deduced that in SCD, spinal cord involvement 
occurs before peripheral nerve involvement. This result is 
compatible with the finding that deep tendon reflexes are 
preserved in SCD patients who complain of numbness in 
the extremities.1,2 Dementia is a known sign of SCD. In this 
study, we did not use any neuropsychiatric tests such as the 
Mini Mental State Examination. However, there was no 
mention of dementia on the medical charts we reviewed 
(data not shown). Therefore, we believe dementia to be the 
last sign of SCD. 
Because SCD is a treatable disease, it is essential to start 
treatment immediately upon diagnosis. Hence, the natural 
course of SCD cannot be followed prospectively, but a cross-
sectional study affords a practical way of studying it.
It is well known that the presence of VB12 deficiency 
alone is not enough to allow for a precise diagnosis of SCD. 
Therefore, for an exact diagnosis, elevated methylmalonic 
acid levels and decreased homocysteine levels must be ob-
served. Unfortunately, there were no records of methylma-
lonic acid or homocysteine levels for the patients in our 
study, and the lack of these data is a potential weak point. 
VB12 deficiency is receiving increasing interest. Diabetes 
mellitus is very highly prevalent in developed countries. 
Metformin, which has been approved for use in the United 
States in 1994, is the first-line drug for the treatment of type 
II diabetes and a recent report has stated that chronic metfor-
min use leads to VB12 deficiency.5 
Because it is difficult to clinically distinguish between 
myeloneuropathy and peripheral neuropathy, and because 
optic neuropathy is often subclinical, we included only 
electrophysiological data. 
MATERIALS AND METHODS
　　　
We conducted a retrospective record review of patients who 
visited our clinic with neurological complaints and whose 
serum VB12 level was lower than 200 pg/mL. These inclu-
sion criteria have been used in previous studies.6,7 We select-
ed patients who had undergone electrophysiology studies 
[median nerve somatosensory evoked potential (MN-SEP), 
posterior tibial nerve somatosensory evoked potential (PT-
SEP), visual evoked potential (VEP), and nerve conduction 
study (NCS)] before VB12 replacement therapy. We ob-
served the electrophysiological patterns of each patient. The 
normal limits of the evoked potentials were P100<110 msec 
(VEP), N19<21.1 msec (MN-SEP), P37<40.9 msec (PT-
SEP). The normal limit of NCS was determined within 2 
standard deviations from the mean value.8 
 
RESULTS
 
We enrolled 49 patients in this study. Their mean age was 
56.4 years, and their average VB12 level was 68.3 pg/mL 
(Table 1). Abnormal SEPs were observed in 38 patients 
(78%); 19 of these showed abnormal findings on both MN-
SEPs and PT-SEPs, 16 showed abnormal findings on PT-
SEPs only, and three showed abnormal findings on MN-
SEPs only. VEP study was performed in 40 patients, of 
which 14 (35%) showed abnormalities; two showed abnor-
mal findings on VEP only, 12 of these 14 also showed ab-
normal SEPs and eight of those 12 patients, in particular, 
showed abnormal both MN-SEPs and PT-SEPs. NCS was 
performed for all 49 patients. Of these, 18 (37%) showed 
abnormal findings; one showed abnormal findings on NCS 
only, 17 of these 18 patients also showed abnormal SEPs, 
and 5 also showed abnormal VEPs (Table 2). 
Table 1. Clinical Summary
Age (yrs), mean (range) 56.4 (16-82)
Male/Female  41/15
Vitamin B12 (pg/mL), mean (range)   68.3 (12-186)
Table 2. Electrophysiological Findings 
Normal Abnormal Not performed
SEP 11 38 0
(PT-SEP) 14 35 0
(MN-SEP) 26 20 3
VEP 26 14 9
NCS 31 18 0
SEP, somatosensory evoked potential; PT, posterior tibial nerve; MN, me-
dial nerve; VEP, visual evoked potential; NCS,  nerve conduction study.Yang-Ki Minn, et al.
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However, normal serum methylmalonic acid and homocys-
teine levels are observed in only 0.2% of patients with 
VB12 deficiency.9
In conclusion, in SCD, degeneration progresses in the 
following sequential order: lower spinal cord, cervical spi-
nal cord, peripheral nerve/optic nerve, and finally, the brain. 
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